

Jesús M Fernández-Gómez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2080979/publications.pdf>

Version: 2024-02-01

58
papers

1,976
citations

430754

18
h-index

243529

44
g-index

75
all docs

75
docs citations

75
times ranked

1990
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of the Hexanic Extract of <i>Serenoa repens</i> vs. Watchful Waiting in Men with Moderate to Severe LUTS-BPH: Results of a Paired Matched Clinical Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 967.	1.0	5
2	Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of <i>Serenoa repens</i> versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3615.	1.0	3
3	Tratamientos actuales tras fracaso a BCG en cáncer de vejiga no músculo-invasivo. <i>Actas Urológicas Españolas</i> , 2021, 45, 93-102.	0.3	16
4	Efficacy and tolerability of the hexanic extract of <i>Serenoa repens</i> compared to tamsulosin in moderate-severe LUTS-BPH patients. <i>Scientific Reports</i> , 2021, 11, 19401.	1.6	11
5	Clinical Benefit of Tamsulosin and the Hexanic Extract of <i>Serenoa Repens</i> , in Combination or as Monotherapy, in Patients with Moderate/Severe LUTS-BPH: A Subset Analysis of the QUALIPROST Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2909.	1.0	16
6	Análisis comparativo de la expresión de metaloproteasas (MMP-2, MMP-9, MMP-11 y MMP-13) y del inhibidor tisular de la metaloproteasa 3 (TIMP-3) entre las biopsias previas negativas y las prostatectomías radicales. <i>Actas Urológicas Españolas</i> , 2020, 44, 78-85.	0.3	3
7	Terapia de privación de andrógenos en pacientes con enfermedad localizada: comparación de las opciones de tratamiento y tiempo hasta la resistencia a la castración. Resultados del Registro Español de Cáncer de Próstata. <i>Actas Urológicas Españolas</i> , 2020, 44, 156-163.	0.3	4
8	Utilidad de la PET/TC 18-FDG en diagnóstico y seguimiento de tumores urológicos uroteliales y renales. <i>Actas Urológicas Españolas</i> , 2019, 43, 32-38.	0.3	0
9	Actualización del papel de la quimioterapia endovesical en el cáncer de vejiga no músculo-invasivo. <i>Actas Urológicas Españolas</i> , 2018, 42, 73-76.	0.3	5
10	Utilidad clínica de las biopsias aleatorias en el diagnóstico y tratamiento del tumor vesical no-músculo invasivo: revisión sistemática y metaanálisis. <i>Actas Urológicas Españolas</i> , 2018, 42, 285-298.	0.3	10
11	Efficacy and safety of a hexanic extract of <i>Serenoa repens</i> (Permixon®) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. <i>BIU International</i> . 2018. 122. 1049-1065.	1.3	69
12	Revisión de la evidencia sobre el manejo de medicamentos y productos peligrosos en los servicios de Urología. Documento de consenso entre la Asociación Española de Urología y la Sociedad Española de Farmacia Hospitalaria. <i>Actas Urológicas Españolas</i> , 2018, 42, 375-380.	0.3	0
13	La consolidación de <i>Actas Urológicas Españolas</i> . <i>Actas Urológicas Españolas</i> , 2018, 42, 423-424.	0.3	0
14	Review of evidence on handling hazardous drugs and Products in Urology Services; consensus document between the Spanish Urology Association and the Spanish Society of Health-System Pharmacists. <i>Farmacia Hospitalaria</i> , 2018, 42, 212-215.	0.6	0
15	Beneficio de la nefrectomía en el tratamiento del carcinoma de células renales metastásico. <i>Actas Urológicas Españolas</i> , 2017, 41, 338-342.	0.3	0
16	Diagnóstico y tratamiento del cáncer de próstata clínicamente localizado. Adherencia a las guías clínicas en un estudio poblacional nacional "GESCAP". <i>Actas Urológicas Españolas</i> , 2017, 41, 359-367.	0.3	12
17	Metaloproteinasa 11, potencial marcador y diana molecular en cáncer de próstata avanzado y resistente a la castración. Estudio in cultivo de fibroblastos peritumorales. <i>Actas Urológicas Españolas</i> , 2017, 41, 376-382.	0.3	3
18	Estimulación transcutánea del nervio tibial posterior en el tratamiento de la incontinencia urinaria de urgencia refractaria, de origen idiopático y neuropático. <i>Actas Urológicas Españolas</i> , 2017, 41, 465-470.	0.3	23

#	ARTICLE	IF	CITATIONS
19	Agradecimiento a los revisores de Actas Urológicas Españolas. Actas Urológicas Españolas, 2017, 41, 605-606.	0.3	0
20	Opciones terapéuticas y factores predictivos de recurrencia y mortalidad cáncer-específica en pacientes con tumor vesical después de trasplante renal: análisis multiinstitucional. Actas Urológicas Españolas, 2017, 41, 639-645.	0.3	10
21	Stromal factors involved in human prostate cancer development, progression and castration resistance. Journal of Cancer Research and Clinical Oncology, 2017, 143, 351-359.	1.2	41
22	MP29-01 TREATMENT OPTIONS AND PREDICTIVE FACTORS FOR RECURRENCE AND CANCER SPECIFIC MORTALITY IN BLADDER CANCER AFTER RENAL TRANSPLANTATION: A MULTIINSTITUTIONAL ANALYSIS. Journal of Urology, 2016, 195, .	0.2	0
23	GnRH antagonist administration to postpone a weekend intrauterine insemination: a large cohort study from a public center. Reproductive Biology and Endocrinology, 2016, 14, 53.	1.4	1
24	La calidad de Actas Urológicas Españolas y sus revisores. Actas Urológicas Españolas, 2016, 40, 595-596.	0.3	6
25	Tendencias de tratamiento en el cáncer de próstata clínicamente localizado. Análisis poblacional a nivel nacional: grupo GESCAP. Actas Urológicas Españolas, 2016, 40, 209-216.	0.3	18
26	Editorial Comment to Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: Long-term follow-up experience at a single institute. International Journal of Urology, 2015, 22, 548-548.	0.5	0
27	Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013. European Urology, 2015, 68, 256-262.	0.9	63
28	Los revisores de Actas Urológicas Españolas. Un privilegio para nuestra urología. Actas Urológicas Españolas, 2015, 39, 595-596.	0.3	0
29	Sequential Combination of Mitomycin C Plus Bacillus Calmette-Guérin (BCG) Is More Effective but More Toxic Than BCG Alone in Patients with Non-muscle-invasive Bladder Cancer in Intermediate- and High-risk Patients: Final Outcome of CUETO 93009, a Randomized Prospective Trial. European Urology, 2015, 67, 508-516.	0.9	54
30	Predictive Factors for Impaired Renal Function following Nephroureterectomy in Upper Urinary Tract Urothelial Cell Carcinoma. Urologia Internationalis, 2014, 92, 169-173.	0.6	20
31	Editorial Comment to External validation of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment scoring models to predict recurrence and progression in Japanese patients with non-muscle invasive bladder cancer treated with bacillus Calmette-Guérin. International	0.5	0
32	Molecular Classification of Non-muscle-Invasive Bladder Cancer (pTa Low-Grade, pT1 Low-Grade, and T1 ETQq000rgBT /Overlock 10 Diagnostics, 2014, 16, 564-572.	1.2	24
33	Polyamine-modulated Factor-1 Methylation Predicts Bacillus Calmette-Guérin Response in Patients with High-grade Non-muscle-invasive Bladder Carcinoma. European Urology, 2013, 63, 364-370.	0.9	23
34	Tratamiento del tumor vesical no músculo infiltrante frente al problema de disponibilidad de bacilo de Calmette-Guerin. Consenso de un panel de expertos españoles. Actas Urológicas Españolas, 2013, 37, 387-394.	0.3	10
35	1875 METHYLATION OF TUMOR SUPPRESSOR GENES PREDICT RECURRENCE AND SUBCLASSIFY NON MUSCLE-INVASIVE DISEASE: PTA LOW GRADE VERSUS PT1 LOW GRADE AND PT1 HIGH GRADE BLADDER TUMORS. Journal of Urology, 2013, 189, .	0.2	0
36	A Quantitative Proteomic Analysis Uncovers the Relevance of CUL3 in Bladder Cancer Aggressiveness. PLoS ONE, 2013, 8, e53328.	1.1	22

#	ARTICLE	IF	CITATIONS
37	Diagnostic Value of Anti-deamidated Gliadin Peptide IgG Antibodies for Celiac Disease in Children and IgA-deficient Patients. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 55, 50-55.	0.9	37
38	656 RANDOMIZED PHASE III TRIAL COMPARING ADJUVANT PACLITAXEL/GEMCITABINE/CISPLATIN (PGC) TO OBSERVATION IN PATIENTS WITH RESECTED INVASIVE BLADDER CANCER: RESULTS OF THE SOGUG-GUO-AEU 99/01 TRIAL. <i>European Urology Supplements</i> , 2011, 10, 212.	0.1	0
39	Peripheral neuropathy: an underdiagnosed cause of erectile dysfunction. <i>BJU International</i> , 2011, 108, 1855-1859.	1.3	15
40	The EORTC Tables Overestimate the Risk of Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: External Validation of the EORTC Risk Tables. <i>European Urology</i> , 2011, 60, 423-430.	0.9	148
41	Relationship between metalloprotease expression in tumour and stromal cells and aggressive behaviour in prostate carcinoma: Simultaneous high-throughput study of multiple metalloproteases and their inhibitors using tissue array analysis of radical prostatectomy samples. <i>Scandinavian Journal of Urology and Nephrology</i> , 2011, 45, 171-176.	1.4	8
42	Myopodin Methylation is Associated With Clinical Outcome in Patients With T1G3 Bladder Cancer. <i>Journal of Urology</i> , 2010, 184, 1507-1513.	0.2	34
43	Retroperitoneal residual mass resection: retroaortic renal vein. <i>Actas Urológicas Españolas (English)</i> 10784314	0.2	0
44	Sympathetic skin response in patients with erectile dysfunction. <i>BJU International</i> , 2009, 104, 1709-1712.	1.3	15
45	Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model. <i>Journal of Urology</i> , 2009, 182, 2195-2203.	0.2	480
46	Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. <i>International Journal of Clinical Practice</i> , 2008, 62, 1076-1086.	0.8	119
47	Prognostic Factors in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials. <i>European Urology</i> , 2008, 53, 992-1002.	0.9	220
48	MO45 Peripheral large fiber neuropathy in patients with erectile dysfunction. <i>Clinical Neurophysiology</i> , 2008, 119, S42.	0.7	0
49	PREDICTION OF RECURRENCE AND PROGRESSION OF NON-MUSCLE INVASIVE BLADDER CANCER IN PATIENTS TREATED WITH BACILLUS CALMETTE-GUÉRIN: A SCORING SYSTEM BASED ON MULTIVARIATE ANALYSIS OF DATA FROM FOUR RANDOMISED CUETO TRIALS. <i>European Urology Supplements</i> , 2008, 7, 298.	0.1	0
50	Significance of Collagenase 3 (Matrix Metalloproteinase 13) in Invasive Bladder Cancer: Correlation with Pathological Parameters. <i>Urologia Internationalis</i> , 2007, 78, 140-144.	0.6	8
51	Determination of a New Cut-Off Value for the Urinary BTAtak to Optimize the Detection of Recurrences in the Follow-Up of Patients with Superficial Bladder Carcinoma. <i>Current Urology</i> , 2007, 1, 42-47.	0.4	0
52	594 FACTORS AFFECTING TUMOR RECURRENCE AND PROGRESSION OF NON-MUSCLE INVASIVE BLADDER CANCER (TA, T1, TIS) TREATED WITH BACILLUS CALMETTE-GUÉRIN. MULTIVARIATE ANALYSIS OF DATA FROM FOUR RANDOMIZED CUETO TRIALS. <i>European Urology Supplements</i> , 2007, 6, 171.	0.1	0
53	Urinary CYFRA 21.1 Is Not a Useful Marker for the Detection of Recurrences in the Follow-Up of Superficial Bladder Cancer. <i>European Urology</i> , 2007, 51, 1267-1274.	0.9	37
54	A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C. <i>European Urology</i> , 2007, 52, 1398-1406.	0.9	170

#	ARTICLE	IF	CITATIONS
55	A new form of presentation of renal actinomycosis: renal tumor with retroperitoneal bleeding. Archivos Espanoles De Urologia, 2006, 59, 756-9.	0.1	3
56	Telomere Length on Bladder Washing Samples from Patients with Bladder Cancer Correlates with Tumor Characteristics. European Urology, 2005, 48, 432-437.	0.9	5
57	HAS A 3-FOLD DECREASED DOSE OF BACILLUS CALMETTE-GUERIN THE SAME EFFICACY AGAINST RECURRENCES AND PROGRESSION OF T1G3 AND TIS BLADDER TUMORS THAN THE STANDARD DOSE? RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL. Journal of Urology, 2005, 174, 1242-1247.	0.2	174
58	Duplicación ciega ureteral asociada a carcinoma transicional de vejiga. Actas Urológicas Españolas, 2003, 27, 568.	0.3	0